

CARMAT

PRESS RELEASE

CARMAT announces the assembly of the first clinical version of its artificial heart

- Achievement of a key milestone announced at the time of the company's successful IPO on NYSE Alternext in July 2010
- These devices will be used for the first-in-man clinical trials scheduled for 2011

Paris, November 18th, 2010

CARMAT, the designer and developer of the world's most advanced artificial heart, today announced that it has completed the assembly of the first clinical version of its artificial heart (to be implanted in humans during clinical trials scheduled for 2011). The devices were assembled in CARMAT's cleanroom facilities (inaugurated in October 2009).

CARMAT CEO Marcello Conviti commented: *"Reaching this key milestone - production of the artificial hearts that will be used in the clinical studies scheduled for 2011 - confirms that we are following the roadmap announced at the time of our IPO. We have achieved these objectives within two years of incorporation and just one year after inaugurating our cleanroom. CARMAT is continuing to implement its strategy for delivering the world's most advanced artificial heart."*

The development of complex bioprotheses is one of the most promising new approaches in medicine. CARMAT embodies the exploitation of research excellence and the convergence of several cutting-edge technologies. The company is now addressing a major challenge in public health with a very significant socio-economic impact.

About CARMAT: CARMAT, the world's most advanced total artificial heart project

The only credible response for all cases of end-stage heart failure, which is a real public health issue: CARMAT's aim is to be able to provide a response to a major public health issue associated with heart disease, the world's leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 100 million patients in developed countries. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure.

The result of the combination of two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of EADS, world aerospace leader.

Imitating the natural heart: given its size, its weight, the choice of structural materials and its innovative physiological functions, CARMAT's total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit the lives of tens of thousands of patients a year whilst ensuring there is no risk of rejection and providing them with an unparalleled quality of life.

A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by OSEO; a total of €33 million.

Substantial involvement of prestigious founders and shareholders: Truffle Capital, the leading European venture capital firm, EADS, the Foundation Alain Carpentier (Carmat's co-founder) and thousands of institutional and individual shareholders who have also shown their confidence in CARMAT.

For more information: www.carmatsas.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Carmat ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French *Autorité des marchés financiers* ("AMF") granted its visa no. n°10-180 on June 14, 2010, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.



CARMAT

Marcello Conviti

CEO

Patrick Coulombier

COO

Tel.: + 33 (0) 1 39 45 54 50

investisseurs@carmatsas.com

ALIZE RP – Corporate Communication

Caroline Carmagnol

Tel.: + 33 (0) 6 64 18 99 59

caroline@alizerp.com

Anne-Sophie Cosquéric

Tel.: + 33 (0) 1 41 68 86 41

anne-sophie@alizerp.com

ALCAR
LISTED
NYSE
ALTERNEXT

Name: **CARMAT**
ISIN code: **FR0010907956**
Ticker: **ALCAR**